Bailard’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bailard’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-57,400	Closed	-$196K	–	803
2021 Q3	$196K	Buy	57,400 +41,000	+250%	+$126K	0.01%	684
2021 Q2	$49K	Buy	+16,400	New	+$51.9K	﹤0.01%	700

Other funds holding INFI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bailard's INFI Position: Q4 2021 in Review

Bailard sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2021, closing a stake of 57,400 shares — an estimated $196K sold.

Bailard first reported a position in INFI in Q2 2021 and held it in 2 quarters. The position peaked at $196K in Q3 2021. 97 funds tracked by Wall St. Rank hold INFI as of Q4 2021.

Bailard reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Bailard sold 57,400 Infinity Pharmaceuticals, Inc. shares in Q4 2021, an estimated $196K.
Bailard first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
Bailard's Infinity Pharmaceuticals, Inc. position peaked at $196K in Q3 2021.
97 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.